

CURRICULUM VITAE

BARRY D. BROOKS, M.D.

OFFICE: Medical City Dallas [REDACTED] [REDACTED]
7777 Forest Lane, D-400 [REDACTED]
Dallas, Texas 75230

PHONE: 972-566-7790 [REDACTED] [REDACTED]

BIRTH PLACE AND DATE: [REDACTED]
[REDACTED]

FAMILY: Children: Two

PREMEDICAL EDUCATION: Texas Tech University, Lubbock, Texas
B.A. in Chemistry, 1972 with honors

MEDICAL SCHOOL: University of Texas Southwestern Medical School,
Dallas, Texas
M.D., 1976 (AOA)

INTERNSHIP AND MEDICAL RESIDENCY: Parkland Memorial Hospital and Dallas VA Hospital
July 1, 1976 - June 30, 1979

FELLOWSHIP: Parkland Memorial Hospital and Dallas VA Hospital
Hematology/Oncology Fellowship
July 1, 1980 - June 30, 1982

LICENSE: [REDACTED]

CERTIFICATION: American Board of Internal Medicine, 1980
American Board Medical Oncology, 1983

HONORARY SOCIETIES AND AWARDS: Alpha Omega Alpha - Medical School Honorary

PROFESSIONAL ASSOCIATIONS: American Society of Clinical Oncology
Texas Medical Association
Dallas County Medical Association
Member, Texas Society of Medical Oncology
American Society of Hematology
Chairman, Texas Medical Association
Committee on Cancer, 2008 - 2011

Texas Medical Association
Committee on Science & Public Health,
2008 - 2011

COMMITTEE MEMBERSHIPS:

Secretary of Medical Staff, Medical City Dallas, 1986
President of Medical Staff, Medical City Dallas, 1989-
1990
Board of Trustees, Medical City Dallas, 1990 - 1992
Medical City Executive Committee, 6 years
Chairman, Department of Medicine, Medical City
Dallas, 1993; 2004 - 2006
Member, Privileges and Credentials Committee,
Medical City Dallas, 1990 - 1994
Board of Trustees, BLOODCARE (Dallas Area
Bloodbank), 1994 - 1997
Board of Trustees, CARTER BLOODCARE (Dallas-
Fort Worth Bloodbank), 1998 - 2008

US ONCOLOGY ADMINISTRATIVE
POSITIONS:

Chairman of Drug Contracting Committee,
2004 - Present

Member, Pathway Task Force Committee
(Supportive Care Subcommittee Chair),
2005 - 2013

Pharmacy & Therapeutics Executive
Committee Member, 2000 - Present

Medical Director and Chairman of US Oncology
P&T Committee, 2011 - Present

PRIVATE PRACTICE:

Medical Oncology (50%), Hematology (50%)
Dallas Diagnostic Association
July 1982 - 1986

Texas Oncology, P.A.
Group Practice
Medical Oncology/Hematology
1986 - Present

PUBLICATIONS:

“Therapeutic Plasma Exchange in Immune
Hemolytic Anemias and immunologic
Thrombocytopenic Purpura.” **PROGRESS IN
CLINICAL AND BIOLOGICAL RESEARCH**,
Volume 106. Page 317 - 330. Alan R. Liss, Inc.

“Therapeutic Plasmapheresis in Patients with
Antibodies to High Frequency Red Cell Antigen.”
E.A. Steane, R.G. Sheehan, **B.D. Brooks**, and

Eugene Frenkel. **PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH**, Volume 106. Page 347 - 354. 1982. Alan R. Liss, Inc.

“Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.” S.E. Jones, R.G. Menzel, G.N. Peters, M.A. Estrick, **B.D. Brooks**, S.M. Knox, and P. McGuffey. **INVESTIGATIONAL NEW DRUGS 6**. pp 195 - 198, 1988. Kluwer

Academic Publishers- Printed in the Netherlands.

“Phase II Study of Mitoxantrone, Leucovorin, and Infusional Fluorouracil for Treatment of Metastatic Breast Cancer.” S.E. Jones, R.G. Menzel **B.D. Brooks**, M.A. Westrick, M.A. Allison, R.S. Paulson, K. Tilman, B. Rea. **JOURNAL OF CLINICAL ONCOLOGY**, Volume 9, Number 10. pp 1736 - 1739, 1991.

ABSTRACTS:

Rosenfeld C, Kerr R, **Brooks B**, White C, Savin M: “Adjuvant Chemotherapy Prior to ASCT for Breast Cancer: Less is More?” **American Society of Clinical Oncology**, Volume 19:232, 2000.

Goldman S, Stafford C, Weinthal J, Kerr R, White C, Savin M, **Brooks B**, Rosenfeld C, Lenarsky C: “Older Adolescents Vary Greatly from Children in Their route of Referral to the Pediatric Oncologist and National Trials.” **American Society of Clinical Oncology**, Volume 19:1766, 2000.

Jones S, **Brooks B**, et al: “Low Proliferative Rate of Invasive Node Negative Breast Cancer Predicts for a Favorable Outcome Without Adjuvant Chemotherapy.” **Proc Am Soc Clin Oncol** 18:70a, 1999 (Abstr 262).

Jones SE, Clark GM, Koleszar S, Ethington G, Menzel R, **Brooks B**, et al: “Five Year Results of Adjuvant Chemotherapy with Adriamycin and Cyclophosphamide (AC) in 450 Women with Invasive Node-Negative Breast Cancer with High S Phase Fraction (SPF).” **Proc Am Soc Clin Oncol** 19:13a, 2000 (Abstr 513).

Neubauer M, Gosse N, Verrilli D, **Brooks B**, et al: “Clinical pathways: are we there yet?” **Community Oncology** March 2013: 96-98.

Jain VK, Ogden J, Cox B, **Brooks B**, et al: "A Phase-II Trial of Infusional Etoposide, Vincristine and Doxorubicin with Bolus Cyclophosphamide (EPOCH) in Patients with Relapsed Hodgkins and Non-Hodgkins-Lymphomas." **Blood** 84:10, A643-A643. 1994.

Brow ME, Okon TA, George ER, Eagle D, Patt DA, Gould B, **Brooks B**, et al: "Thoughts and recommendations on cancer care site of service." **Community Oncology** 9, no. 12(2012): 382-388.

Hoverman JR, Sheth S, Clayton M, Neubauer M, **Brooks B**, et al: "Pemetrexed/cisplatin (pem/cis) Vs. Pemetrexed/carboplatin (pem/carbo) in Non-squamous, Non-small Cell Lung Cancer (nslc): A Retrospective Comparison Using A Large Electronic Database." **J Thor Onc**, Vol. 7, no. 9, pp. S273-S273, 2012.

Patt DA, Espirito JL, Turnwald B, Hoverman J R, Neubauer MA, Cartright TH, Busby LT, **Brooks B**, et al: "Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community." **J Clin Onc**, vol. 30, no. 15 (2012).

Brooks B: "Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. **Inv New Drugs**, September 1988. Vol. 6(3), pp 195-198.

Kolodziej M, Hoverman JR, Garey JS, Espirito J, Sheth S, Ginsburg A, Neubauer MA, Patt D, **Brooks B**, et al: "Benchmarks for Value in Cancer Care: An Analysis of a Large Commercial Population." **J Oncol Pract**, September 2011, vol. 7 no. 5, 301-306.

CURRENT RESEARCH:

Principal Investigator (TOPA) "A Randomized, Open-Label, Phase III Trial of Decitabine (5-AZA-2'-Deoxycytidine) Versus Supportive Care in Adults With Advanced-Stage Myelodysplastic Syndrome." - Closed 2002.


Principal Investigator (TOPA) "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (Thalomid) For The Treatment Of Anemia In Red Blood Cell Transfusion Dependent Patients With Myelodysplastic Syndromes." - Closed 2002.

Principal Investigator “A Multi-Cancer, Randomized Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes.” - USON Trial 04109. Closed April 2007.

**Committee on Energy and Commerce
U.S. House of Representatives**

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1. Your Name: Barry D. Brooks, MD		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
3. Are you testifying on behalf of an entity that is not a government entity?	Yes x	No
4. Other than yourself, please list which entity or entities you are representing: The US Oncology Network Texas Oncology		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011: N/A		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: Chairman, P&T Committee, The US Oncology Network Partner, Texas Oncology		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No x
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: N/A		
9. Please attach your curriculum vitae to your completed disclosure form.		



Signature: _____ Date: 5-20-14